Maintenance<unk>  has shown efficacy to prevent asthma attacks. It is unclear if the efficacy of<unk>  differs from that of fluticasone and salmeterol in chronic asthma. Exacerbation The combination is approved in the United States only as a maintenance medication in asthma and chronic obstructive pulmonary disease (COPD). However, a 2020 review of the literature does support use as needed during acute worsening in those with mild disease, and as maintenance followed by extra doses during worsening. Use for both maintenance and as-needed treatment is also known as single maintenance and reliever therapy (SMART) and is a well-established treatment. It has been shown to, 1) reduce asthma exacerbations that require oral corticosteroids, 2) reduce hospital visits better than maintenance on inhaled corticosteroids alone at a higher dose, or 3) inhaled corticosteroid at the same or higher dose together with a long-acting bronchodilator (LABA), with a short-acting bronchodilator (SABA) as a reliever.
Budesonide/formoterol
Beclometasone/formoterol/glycopyrronium bromide
Mometasone/formoterol
Beclometasone/formoterol
Aclidinium bromide/formoterol
Fluticasone/salmeterol
Budesonide/glycopyrronium bromide/formoterol
Glycopyrronium bromide/formoterol